Hydroxypropyl-β-Cyclodextrin: Domestic Innovation Drives Global Value Chain Upgrading

As a highly water-soluble functional cyclodextrin derivative, hydroxypropyl-β-cyclodextrin (HP-β-CD) has played an irreplaceable role in encapsulation, solubilization, and stabilization across industries such as pharmaceuticals, food, and cosmetics, thanks to its unique "hydrophobic interior and hydrophilic exterior" cavity structure. In recent years, driven by the growing global demand for solubilization technologies targeting poorly soluble drugs in the pharmaceutical sector and the deep transformation of the cosmetics industry toward performance-driven formulations, this niche market is experiencing rapid growth. Industry data shows that from 2022 to 2025, the global cyclodextrin derivatives market achieved an average annual compound growth rate of 12.8%, with HP-β-CD consumption in pharmaceutical excipients rising at approximately 15% per year.

Against the backdrop of domestic substitution and international expansion, China has emerged as a key production and R&D hub for HP-β-CD. Domestic enterprises have made significant progress through continuous technological breakthroughs in synthesis processes, impurity control, and product stability. Multiple products have obtained ISO certification and been registered under the Drug Master Files (DMFs) in Europe and the United States, exporting to dozens of countries and regions worldwide. Since 2026, several Chinese manufacturers' HP-β-CD excipients have successfully passed the National Medical Products Administration's (NMPA) linked review process, transitioning their registration status to active, thereby providing downstream formulation companies with a more reliable domestic supply chain. Meanwhile, at recent international cosmetic ingredient exhibitions, Chinese cyclodextrin companies showcased their core encapsulation technology, offering innovative raw material solutions combining moisturizing repair and controlled release of active ingredients—drawing widespread attention from the global beauty industry.

Technological innovation remains the core driver of industry advancement. In April 2026, a research breakthrough in HP-β-CD encapsulation technology enabled its successful application in developing aqueous formulations of estradiol benzoate. The drug’s solubility increased nearly 40,000-fold in HP-β-CD solution, enabling stable attainment of clinically required concentrations. This achievement offers a novel approach to addressing adverse effects associated with traditional oil-based injections and improving clinical safety. Simultaneously, a domestic research team introduced the innovative concept of "multidisperse ultra-multicomponent metal-organic frameworks," using HP-β-CD as a ligand to construct new inhalation drug carriers, demonstrating broad potential in respiratory disease treatment.

Looking ahead, the development of HP-β-CD will continue to deepen along the dimensions of functionality, environmental sustainability, and regulatory compliance. With the full implementation of updated GMP guidelines for excipient regulation and ongoing advancements in cosmetics efficacy evaluation standards, market demand for high-purity, high-stability products with end-to-end quality traceability is expected to surge. From injectable pharmaceuticals to performance-driven cosmetics, from food flavorings to precision agriculture, HP-β-CD is leveraging molecular encapsulation technology to catalyze upgrades and transformations across multiple industrial sectors, injecting renewed vitality into the health and beauty industries.